In this systematic review, which included 14340 patients over five trials, we were able to conclude that SGLT2 inhibitors and MRAs reduced the risk of worsening heart failure events and cardiovascular deaths compared to placebo [15-19]. The gene discussed is SLC5A2; the disease is heart failure.